Compared with CNI-based immunosuppression, mTOR-inhibitor-based immunosuppression significantly increased recurrence-free-survival at both 1- and 3-years post-transplantation (risk ratio [RR] 1.09 and 1.1, respectively) in a systematic review and meta-analysis of 23 studies on the survival and recurrence of HCC in liver transplant recipients [55]. This evidence concerns the gene MTOR and hepatocellular carcinoma.